In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

ADRs lost ~15% in the premarket on Tuesday after the Danish drugmaker lowered its full-year outlook, citing, among other ...

The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen ...

Novo Nordisk selloff is an overreaction. With solid fundamentals, a strong drug pipeline & long-term upside, discover why ...

Novo Nordisk’s shares plunged more than a fifth on Tuesday, wiping more than €60bn from its value, after it slashed sales and profit forecasts for the year amid competition from US copycat weight-loss ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...